Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics IncfiledCriticalIovance Biotherapeutics Inc
Publication of AR119671A2publicationCriticalpatent/AR119671A2/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
En la presente se divulgan métodos para expandir linfocitos infiltrantes de tumores (LIT) a partir de sangre o médula ósea de pacientes con neoplasias malignas hematológicas, tales como tumores líquidos, que incluyen linfomas y leucemias, y usos de tales LIT expandidos en el tratamiento de enfermedades tales como cánceres y neoplasias malignas hematológicas.Methods of expanding tumor-infiltrating lymphocytes (TILs) from blood or bone marrow of patients with hematologic malignancies, such as liquid tumors, including lymphomas and leukemias, and uses of such expanded LITs in the treatment of hematologic malignancies are disclosed herein. diseases such as cancers and hematologic malignancies.
ARP200100035A2017-05-102020-01-07
EXPANSION OF INFILTRATING LYMPHOCYTES OF LIQUID TUMORS AND THERAPEUTIC USE OF THE SAME
AR119671A2
(en)
USE OF AN INHIBITOR OF THE DYMERIZATION OF THEROSINE KINASE RECEIVERS HER FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO EXTEND THE TIME UNTIL THE PROGRESSION OF THE DISEASE OR SURVIVAL OF CANCER PATIENTS
Phosphoramidochloride morpholino nucleosides activated diastereomerically pure or substantially diastereomerically pure and methods for their preparation